Neuphoria Therapeutics
(NASDAQ) NEUP
Neuphoria Therapeutics Financials at a Glance
Market Cap
$23.29M
Revenue (TTM)
-$10.47M
Net Income (TTM)
-$27.55M
EPS (TTM)
-$23.89
P/E Ratio
-0.18
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$4.29
Volume
2,560
Open
$4.11
Price
$4.29
Volume
2,560
Open
$4.11
Previous Close
$4.29
Daily Range
$4.00 - $4.29
52-Week Range
$3.65 - $21.40
Estimated Earnings Date
Sep 2, 2026
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$4.29
Volume
2,560
Open
$4.11
Previous Close
$4.29
Daily Range
$4.00 - $4.29
52-Week Range
$3.65 - $21.40
Estimated Earnings Date
Sep 2, 2026
NEUP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Neuphoria Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
8
CEO
Spyridon Papapetropoulos, MD, PhD
Website
www.neuphoriatx.comHeadquarters
Burlington, US
NEUP Financials
Key Financial Metrics (TTM)
Gross Margin
1%
Operating Margin
3%
Net Income Margin
3%
Return on Equity
0%
Return on Capital
-79%
Return on Assets
-79%
Earnings Yield
-5.56%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$23.29M
Shares Outstanding
5.40M
Volume
2.56K
Avg. Volume
53.72K
Financials (TTM)
Gross Profit
$15.65M
Operating Income
-$1.13M
EBITDA
-$121.90K
Operating Cash Flow
$77.23M
Capital Expenditure
$0.00
Free Cash Flow
$77.23M
Cash & ST Invst.
$21.59M
Total Debt
$226.49K
Neuphoria Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$165.70K
-100.7%
Gross Margin
0.00%
N/A
Market Cap
$23.29M
N/A
Market Cap/Employee
$2.91M
N/A
Employees
8
N/A
Net Income
-$505.06K
-102.7%
EBITDA
-$1.00M
-105.0%
Quarterly Fundamentals
Total Cash
$19.44M
+14.1%
Total Debt
$34.23K
-80.2%
Accounts Receivable
$1.61M
+6427.9%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$34.23K
-77.7%
Return on Assets
-79.16%
N/A
Return on Invested Capital
-78.65%
N/A
Free Cash Flow
-$3.87M
-133.8%
Operating Cash Flow
-$3.87M
-133.8%